Short answer
Biomarin Pharmaceutical Inc (BMRN) filed an 8-K current report with the SEC on September 15, 2026 reporting Item 8.01 (Other Events). BioMarin discontinued VOXZOGO development for children with Noonan syndrome.
Biomarin Pharmaceutical Inc 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- BioMarin discontinued VOXZOGO development for children with Noonan syndrome
- Decision reflects study feasibility and the existing treatment landscape
- Discontinuation was not related to VOXZOGO safety or efficacy
- Strategic impact: reduced expansion opportunity for VOXZOGO in Noonan syndrome, without a disclosed product safety setback
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Biomarin Pharmaceutical Inc 8-K filings
Get the next BMRN 8-K as it lands
Follow BMRN for push alerts, or ask the research agent what this filing means.